To analyze the effect of PAR2 antagonist (AZ3451) on phospholipid metabolism, we performed a phospholipid analysis to compare the hyperuricemia group with the HU + AZ3451 group at 6 weeks post-AZ3451 intraperitoneal injection. Here, F2RL1 is linked to hyperuricemia.